platoseedplatoseed
ExcepGen develops RNA-based vaccines and therapies that dampen excessive innate immune responses to nucleic acids and lipid nanoparticles, aiming for tolerability closer to standard of care. Their RNAx platform encodes proteins that modulate cellular responses to RNA and LNPs to improve vaccine tolerability.
RNAx platform delivers an mRNA-encoded protein that alters how cells respond to RNA and LNPs, specifically dampening an overactive innate immune response to nucleic acids. This approach targets improved tolerability for RNA-based vaccines and related nucleic acid therapies, pursuing self-amplifying and trans-amplifying mRNA vaccine concepts as core initiatives.
Who it’s for: Biotech/pharma companies and researchers developing RNA-based vaccines and nucleic acid therapeutics that require improved innate immune tolerability.
Hiring/traction mentions (team and careers), research-focused growth
AI platform accelerating therapies for rare & inflammatory diseases.
Creating a New Class of Drugs to Address Incurable Autoimmune Diseases
